IEQ Capital’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-16,067
Closed -$56.7K 1884
2025
Q4
$56.7K Sell
16,067
-4,531
-22% -$18.4K ﹤0.01% 1798
2025
Q3
$82.4K Buy
20,598
+298
+1% +$939 ﹤0.01% 1777
2025
Q2
$54.4K Sell
20,300
-2,625
-11% -$5.52K ﹤0.01% 1760
2025
Q1
$32.3K Buy
+22,925
New +$39K ﹤0.01% 1573

Other funds holding ADCT

IEQ Capital's ADCT Position: Q1 2026 in Review

IEQ Capital sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 16,067 shares — an estimated $56.7K sold.

IEQ Capital first reported a position in ADCT in Q1 2025 and held it in 4 quarters. The position peaked at $82.4K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • IEQ Capital reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IEQ Capital sold 16,067 ADC Therapeutics shares in Q1 2026, an estimated $56.7K.
  • IEQ Capital first reported a position in ADC Therapeutics in Q1 2025 and held it in 4 quarters.
  • IEQ Capital's ADC Therapeutics position peaked at $82.4K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.